Kura Oncology (KURA) Announces Preliminary Clinical & Pre-Clinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Tweet Send to a Friend
Kura Oncology, Inc. (NASDAQ: KURA) today announced that clinical and preclinical data for tipifarnib in the treatment of relapsed or ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
